Global Trends and Emerging Insights in BRAF and MEK Inhibitor Resistance in Melanoma: a Bibliometric Analysis

Overview

Journal Front Mol Biosci

Date 2025 Feb 3

PMID 39897423

Authors

Jianhao Bai

Zhongqi Wan

Wanru Zhou

Lijun Wang

Wei Lou

Yao Zhang

Haiying Jin

Affiliations

Soon will be listed here.

Abstract

Objective: This study aims to perform a comprehensive bibliometric analysis of global research on BRAF and MEK inhibitor resistance in melanoma, identifying key research trends, influential contributors, and emerging themes from 2003 to 2024.

Methods: A systematic search was conducted in the Web of Science Core Collection (WoSCC) database to retrieve publications related to BRAF and MEK inhibitor resistance from 1 January 2003, to 1 September 2024. Bibliometric analyses, including publication trends, citation networks, and keyword co-occurrence patterns, were performed using VOSviewer and CiteSpace. Collaborative networks, co-cited references, and keyword burst analyses were mapped to uncover shifts in research focus and global cooperation.

Results: A total of 3,503 documents, including 2,781 research articles and 722 review papers, were analyzed, highlighting significant growth in this field. The United States, China, and Italy led in publication volume and citation impact, with Harvard University and the University of California System among the top contributing institutions. Research output showed three phases of growth, peaking in 2020. Keyword and co-citation analyses revealed a transition from early focus on BRAF mutations and MAPK pathway activation to recent emphasis on immunotherapy, combination therapies, and non-apoptotic cell death mechanisms like ferroptosis and pyroptosis. These trends reflect the evolving priorities and innovative approaches shaping the field of resistance to BRAF and MEK inhibitors in melanoma.

Conclusion: Research on BRAF and MEK inhibitor resistance has evolved significantly. This analysis provides a strategic framework for future investigations, guiding the development of innovative, multi-modal approaches to improve treatment outcomes for melanoma patients.

References

Wang B, Zhang W, Zhang G, Kwong L, Lu H, Tan J . Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene. 2021; 40(37):5590-5599. PMC: 8445818. DOI: 10.1038/s41388-021-01911-5. View

Shalhout S, Miller D, Emerick K, Kaufman H . Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023; 20(3):160-177. DOI: 10.1038/s41571-022-00719-w. View

Bakr El-Nassan H . Recent progress in the identification of BRAF inhibitors as anti-cancer agents. Eur J Med Chem. 2014; 72:170-205. DOI: 10.1016/j.ejmech.2013.11.018. View

Poulikakos P, Sullivan R, Yaeger R . Molecular Pathways and Mechanisms of BRAF in Cancer Therapy. Clin Cancer Res. 2022; 28(21):4618-4628. PMC: 9616966. DOI: 10.1158/1078-0432.CCR-21-2138. View

Gide T, Wilmott J, Scolyer R, Long G . Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. Clin Cancer Res. 2017; 24(6):1260-1270. DOI: 10.1158/1078-0432.CCR-17-2267. View

Amaria R, Reddy S, Tawbi H, Davies M, Ross M, Glitza I . Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018; 24(11):1649-1654. PMC: 6481682. DOI: 10.1038/s41591-018-0197-1. View

Hanrahan A, Chen Z, Rosen N, Solit D . BRAF - a tumour-agnostic drug target with lineage-specific dependencies. Nat Rev Clin Oncol. 2024; 21(3):224-247. PMC: 11857949. DOI: 10.1038/s41571-023-00852-0. View

Sun C, Wang L, Huang S, Heynen G, Prahallad A, Robert C . Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014; 508(7494):118-22. DOI: 10.1038/nature13121. View

Muley A, Kim Uh M, Salazar-De Simone G, Swaminathan B, James J, Murtomaki A . Unique functions for Notch4 in murine embryonic lymphangiogenesis. Angiogenesis. 2021; 25(2):205-224. PMC: 9054879. DOI: 10.1007/s10456-021-09822-5. View

10.

Garcia-Mulero S, Alonso M, Del Carpio L, Sanz-Pamplona R, Piulats J . Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression. Int J Mol Sci. 2021; 22(5). PMC: 7961481. DOI: 10.3390/ijms22052669. View

11.

Yin C, Zhu B, Zhang T, Liu T, Chen S, Liu Y . Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis. Cell. 2019; 176(5):1113-1127.e16. DOI: 10.1016/j.cell.2019.01.002. View

12.

Arkenau H, Kefford R, Long G . Targeting BRAF for patients with melanoma. Br J Cancer. 2010; 104(3):392-8. PMC: 3049553. DOI: 10.1038/sj.bjc.6606030. View

13.

Shain A, Bastian B . From melanocytes to melanomas. Nat Rev Cancer. 2016; 16(6):345-58. DOI: 10.1038/nrc.2016.37. View

14.

Mologni L, Costanza M, Sharma G, Viltadi M, Massimino L, Citterio S . Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells. Neoplasia. 2018; 20(5):467-477. PMC: 5915992. DOI: 10.1016/j.neo.2018.02.009. View

15.

Zhang W . BRAF inhibitors: the current and the future. Curr Opin Pharmacol. 2015; 23:68-73. DOI: 10.1016/j.coph.2015.05.015. View

16.

Tan Z, He Q, Feng S . The collision of ChatGPT and traditional medicine: a perspective from bibliometric analysis. Int J Surg. 2023; 109(11):3713-3714. PMC: 10651228. DOI: 10.1097/JS9.0000000000000662. View

17.

Flaherty K, Robert C, Hersey P, Nathan P, Garbe C, Milhem M . Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367(2):107-14. DOI: 10.1056/NEJMoa1203421. View

18.

Blass E, Ott P . Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021; 18(4):215-229. PMC: 7816749. DOI: 10.1038/s41571-020-00460-2. View

19.

Redondo-Munoz M, Rodriguez-Baena F, Aldaz P, Caballe-Mestres A, Moncho-Amor V, Otaegi-Ugartemendia M . Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy. Nat Metab. 2023; 5(9):1544-1562. PMC: 10513932. DOI: 10.1038/s42255-023-00861-4. View

20.

Nissan M, Pratilas C, Jones A, Ramirez R, Won H, Liu C . Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 2014; 74(8):2340-50. PMC: 4005042. DOI: 10.1158/0008-5472.CAN-13-2625. View